ROCKVILLE, Md., April 19 /PRNewswire/ -- Protiveris Inc., a bio-nanotechnology company commercializing microcantilever technologies to facilitate biomolecular research, today announced the appointment of Gregory Kellogg Ph.D. as Chief Technology Officer.
"I am very pleased to welcome Greg to the Protiveris management team. He has been key in building the success of several groundbreaking biotechnology companies, including Network Biosystems and Tecan Boston," said Robert Menzi, Chief Operating Officer at Protiveris. "Greg's skill and depth of experience complement our existing management strengths and we look forward to his contribution to the further development and commercialization of our VeriScan System."
Dr. Kellogg brings to Protiveris a strong history of innovation in developing technology and building R&D organizations. Formerly Vice President of Research at Network Biosystems, Dr Kellogg managed the development of a microfabrication-based electrophoresis system for forensic applications. Prior positions include Director of R&D at IQUUM, where he planned and executed product development feasibility programs, and Chief Scientist at Tecan Boston (formerly Gamera Bioscience Corporation), where he developed the technical foundation of the company's microfluidic platform. This technology was introduced into the drug discovery marketplace as the LabCD(TM), an automation-compatible system for ADMET. Dr. Kellogg received his Ph.D. in physics from Harvard University and conducted his post-doctoral research at Massachusetts Institute of Technology in the Department of Materials Science and Engineering. He has published extensively and is an inventor on more than 10 issued US and European patents.
About Protiveris, Inc.
Protiveris is committed to establishing the standard of performance for proteomic research tools. The VeriScan(TM) 3000 bench-top biochip system measures and analyzes biomolecular and chemical interactions to enable more efficient and accurate research outcomes. The biochip utilizes arrays of microcantilevers with customizable surfaces to detect interactions between proteins, antibodies, antigens, or DNA. This label-free system provides researchers with the ability to create high content assays that deliver real time data. More information about Protiveris, their technology, products, and services can be found at the company's web site at http://www.protiveris.com/ .
CONTACT: Robert Menzi, Chief Operating Officer, +1-301-738-7800 email@example.com